First-Trimester Screening for Trisomy 21 by Free Beta-Human Chorionic Gonadotropin and Pregnancy-Associated Plasma Protein-A : Impact of Maternal and Pregnancy Characteristics

In pregnancies complicated by fetal trisomy 21, maternal serum levels of free-human chorionic gonadotropin (free β-hCG) are about twice as high as in pregnancies with a euploid fetus, while levels of pregnancy-associated plasma protein-A (PAPP-A) are reduced by about half. Screening for trisomy 21 using these markers in addition to fetal nuchal translucency thickness has been reported to detect about 90% of affected pregnancies at a false-positive rate of 5%. However, currently the only variables for which adjustments are made are maternal weight and gestational age. To determine if other maternal variables influence screening test results, the present multicenter trial prospectively screened women in the first-trimester of pregnancy for trisomy 21, using multiple regression analysis to learn how maternal factors, particularly ethnic origin, influenced measured levels of β-hCG and PAPP-A. Gaussian distributions were fitted to the distribution of log multiples of the median values in 491 cases of trisomy 21 and 96,803 euploid pregnancies. Compared with Caucasian women who were parous, nonsmokers, and conceived spontaneously, PAPP-A levels were 57% higher in women of Afro-Caribbean origin, 3% higher in South Asians, 9% higher in East Asians, 2% higher in nulliparous women, 17% lower in smokers, and 10% lower in women who conceived by in vitro fertilization (IVF). Maternal serum levels of free β-hCG were 12% higher in women of Afro-Caribbean origin, 9% lower in South Asian women, 8% higher in East Asians, 2% higher in nulliparous women, 4% lower in smokers, and 9% higher in women who conceived by IVF. If no adjustments were made for variables other than maternal age and gestational age, integrated first-trimester screening based on maternal age-related risk and serum PAPP-A and free β-hCG levels resulted in the detection of 51% of all cases of trisomy at a false-positive rate of 1.4% in Afro-Carribean women; after adjustment for race, the detection increased to 68% at a false-positive rate of 4.6%. Similar changes in the detection and false-positive rates occurred after adjustment for smoking, conception by IVF, and parity. In addition, screening was considerably more sensitive when carried out at 11-12 weeks' gestation rather than at 13 weeks. These results indicate that numerous maternal and pregnancy-related factors must be taken into account when screening in the first-trimester of pregnancy for trisomy 21.

[1]  K. Kagan,et al.  Dose dependency between cigarette consumption and reduced maternal serum PAPP‐A levels at 11–13+6 weeks of gestation , 2007, Prenatal diagnosis.

[2]  F. Malone,et al.  Comparison of Serum Markers in First-Trimester Down Syndrome Screening , 2006, Obstetrics and gynecology.

[3]  K. Nicolaides,et al.  Prospective first-trimester screening for trisomy 21 in 30,564 pregnancies. , 2005, American journal of obstetrics and gynecology.

[4]  K. Spencer,et al.  Ethnicity and the need for correction of biochemical and ultrasound markers of chromosomal anomalies in the first trimester: a study of Oriental, Asian and Afro‐Caribbean populations , 2005, Prenatal diagnosis.

[5]  K. Nicolaides,et al.  Multicenter study of first‐trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk‐orientated two‐stage first‐trimester screening , 2005, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[6]  K. Nicolaides,et al.  The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy , 2004, Prenatal diagnosis.

[7]  K. Nicolaides,et al.  Maternal weight correction of maternal serum PAPP‐A and free β‐hCG MoM when screening for trisomy 21 in the first trimester of pregnancy , 2003, Prenatal diagnosis.

[8]  K. Nicolaides,et al.  Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one‐stop clinic: a review of three years prospective experience , 2003, BJOG : an international journal of obstetrics and gynaecology.

[9]  K. Spencer,et al.  Temporal Changes in Maternal Serum Biochemical Markers of Trisomy 21 across the First and Second Trimester of Pregnancy , 2002, Annals of clinical biochemistry.

[10]  K. Nicolaides,et al.  First-trimester screening for trisomy 21 in singleton pregnancies achieved by assisted reproduction. , 2001, Human reproduction.

[11]  K. Nicolaides,et al.  The influence of ethnic origin on first trimester biochemical markers of chromosomal abnormalities , 2000, Prenatal diagnosis.

[12]  K. Nicolaides,et al.  A screening program for trisomy 21 at 10–14 weeks using fetal nuchal translucency, maternal serum free β‐human chorionic gonadotropin and pregnancy‐associated plasma protein‐A , 1999, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[13]  K. Nicolaides,et al.  UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10–14 weeks of gestation , 1998, The Lancet.

[14]  J. Fleming,et al.  A CRITICAL EVALUATION OF SONAR “CROWN‐RUMP LENGTH” MEASUREMENTS , 1975, British journal of obstetrics and gynaecology.

[15]  N J Wald,et al.  First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). , 2003, Health technology assessment.